

12

**EUROPEAN PATENT APPLICATION**

21 Application number: **88850188.9**

22 Date of filing: **30.05.88**

51 Int. Cl. 4: **C 12 N 15/00**  
**C 12 N 1/20, C 12 P 21/02,**  
**C 07 K 13/00**  
**/(C12N1/20,C12R1:19)**

30 Priority: **01.06.87 SE 8702272**

43 Date of publication of application:  
**07.12.88 Bulletin 88/49**

84 Designated Contracting States:  
**AT BE CH DE ES FR GB GR IT LI LU NL SE**

71 Applicant: **ALFA-LAVAL AGRI INTERNATIONAL AB**  
**Farm Center P.O. Box 39**  
**S-147 00 Tumba (SE)**

72 Inventor: **Höök, Magnus**  
**4734 Bridge Water Road**  
**Birmingham Alabama 35243 (US)**

**Lindberg, Martin Kjell**  
**Kornvägen 5**  
**S-752 57 Uppsala (SE)**

**Signäs, Lars Christer**  
**Hamnesplanaden 2A**  
**S-753 23 Uppsala (SE)**

**Wadström, Torkel Mikael**  
**Rektorsvägen 7**  
**S-223 67 Lund (SE)**

**Fröman, Gunnar**  
**Lindsbergsgatan 5B**  
**S-752 40 Uppsala (SE)**

74 Representative: **Inger, Lars Ulf Bosson**  
**L + U INGER Patentbyrå AB Garvaregatan 12**  
**S-262 00 Ängelholm (SE)**

The microorganism(s) has (have) been deposited with Deutsche Sammlung von Mikroorganismen under number(s) **DSM 4124**.

54 A fibronectin binding protein as well as its preparation.

57 The present invention relates to a new recombinant hybrid-DNA-molecule comprising a nucleotide sequence from *S. aureus* coding for a protein, or polypeptide, having fibronectin binding properties.

Val Lys Asn Asn Leu Arg Tyr Gly Ile Arg Lys His Lys Leu Gly Ala -21  
TGCATTATTAAATTTAAAAAATTAATGAATTTTGCATTAAAGGAGATATTATA GTG AAA AAC AAT CTT AGG TAC GGC ATT AGA AAA CAT AAA TTG GGA GCA 104

Ala Ser Val Phe Leu Gly Thr Met Ile Val Val Gly Met Gly Gln Asn Lys Glu Ala Ala Ala Ser Glu Gln Lys Thr Thr Thr Val Glu 10  
GCA TCA GTA TTC TTA GGA ACA ATG ATC GTT GGT GGG ATG GGA ACA GAC AAA GAA GCT GCA GCA TCA GAA CAA AAG ACA ACT ACA GTA GAA 194

Glu Asn Gly Asn Ser Ala Thr Asp Asn Lys Thr Ser Glu Thr Gln Thr Thr Ala Thr Asn Val Asn His Ile Glu Glu Thr Arg Ser Tyr 40  
GAA AAT GGG AAT TCA GCT ACT GAT AAT AAA ACA AGT GAA ACA CAA ACA ACT GCA ACT AAC GTT AAT CAT ATA GAA GAA ACT CGA TCA TAT 284

Asn Ala Thr Val Thr Glu Gln Pro Ser Asn Ala Thr Gln Val Thr Thr Glu Glu Ala Pro Lys Ala Val Gln Ala Pro Gln Thr Ala Gln 70  
AAC GCA ACA GTA ACA GAA CAA CCG TCA AAC GCA ACA CAA GTA ACA ACT GAA GAA GCA CCA AAA GCA GTA CAA GCA CCA CAA ACT GCA CAA 174

Pro Ala Asn Ile Glu Thr Val Lys Glu Glu Val Val Lys Glu Glu Ala Lys Pro Arg Val Lys Glu Thr Thr Gln Ser Gln Asp Asn Ser 100  
CCA GCA AAT ATA GAA ACA GTT AAA GAA GAG GTA GTT AAG GAA GAA GCG AAA CCT CGA GTT AAG GAA ACA ACA CAA TCT CAA GAC AAT AGC 464

Gly Asp Gln Arg Gln Val Asp Leu Thr Pro Lys Lys Ala Thr Gln Asn Gln Val Ala Glu Thr Gln Val Glu Val Ala Gln Pro Arg Thr 130  
GGA GAT CAA AGA CAA GTA GAT TTA ACA CCT AAA AAG GCT ACA CAA AAT CAA GTC GCA GAA ACA CAA GTT GAA GTG GCA CAG CCA AGA ACG 554

Ala Ser Glu Ser Lys Pro Arg Val Thr Arg Ser Ala Asp Val Ala Glu Ala Lys Glu Ala Ser Asn Ala Lys Val Glu Thr Gly Thr Asp 160  
GCA TCA GAA AGT AAG CCA CGT GTG ACA AGA TCA GCA GAT GTA GCG GAA GCT AAG GAA GCT AGT AAC GCG AAA GTC GAA ACG GGT ACA GAT 644

Val Thr Ser Lys Val Thr Val Gly Ser Ile Glu Gly Ser Ile Glu Gly Ser Lys Asn Asn Thr Asn Lys Val Glu Pro His Ala Gly Gln Arg Ala Val 190  
GTA ACA AGT AAA GTT ACA GTA GAA ATT GGT TCT ATT GAG GGG CAT AAC AAT ACA AAT AAA GTA GAA CCT CAT GCA GGA CAA CGA GCG GTA 734

Leu Lys Tyr Lys Leu Lys Phe Glu Asn Gly Leu His Gln Gly Asp Tyr Phe Asp Phe Thr Leu Ser Asn Asn Val Asn Thr His Gly Val 220  
CTA AAA AAT AAT TTA TAC AAT AAA GGT TTA CAT CAA GGT GAC TAT TTT GAC TTT ACT TTA TCA AAT AAT GTA AAT ACG CAT GGC GTA 824

Ser Thr Ala Arg Lys Val Pro Glu Ile Lys Asn Gly Ser Val Val Met Ala Thr Thr Glu Val Leu Glu Gly Gly Lys Ile Arg Tyr Thr 250  
TCA ACT GCT AGA AAA GTA CCA GAA ATT AAA AAT GGT TCA GTC GTA ATG GCG ACA GGT GAA GTT TTA GAA GGT GGA AAG ATT AGA TAT ACA 914

Phe Thr Asn Asp Ile Gln Asp Lys Val Asp Val Thr Ala Glu Leu Gly Ile Asn Leu Phe Ile Asp Pro Lys Thr Val Gln Thr Asn Gly 280  
TTT ACA AAT GAT ATT CAA GAT AAG GTT GAT GTA ACG GCT GAT GAA ATT AAT TTA TTT ATT GAT CCT AAA ACT GAA AAT GGT GAT AAT GGA 1004

Asn Gln Thr Ile Thr Ser Thr Leu Asn Glu Glu Gln Thr Ser Lys Glu Leu Asp Val Lys Tyr Lys Asp Gly Ile Gly Asn Tyr Tyr Ala 310  
AAT CAA ACT ATA ACT TCA ACA CTA AAT GAA GAA CAA ACT TCA AAG GAA TTA GAT GTT AAA TAT AAA GAT GGT ATT GGG AAT TAT TAT GCC 1094

Asn Leu Asn Gly Ser Ile Glu Thr Phe Asn Lys Ala Asn Asn Arg Phe Thr Ser His Val Ala Phe Ile Lys Pro Asn Asn Gly Lys Thr Thr 340  
AAT TTA AAT GGA TCG ATT GAG ACA TTT AAT AAA GCG AAT AAT AGT TTT TCG CAT GTT GCA TTT ATT AAA CCE AAT AAT GGT AAA ACG ACA 1184

Ser Val Thr Val Thr Gly Thr Leu Met Lys Gly Ser Asn Gln Asn Gly Asn Gln Pro Lys Val Arg Ile Phe Glu Tyr Leu Gly Asn Asn 370  
AAT GTG ACT GTT ACT GGA ACT TTA ATG AAA GGT AGT AAT CAG AAT GAA AAT CAA CCA AAA GTT AGG ATA TTT GAA TAC TTG GGT AAT AAT 1274

Glu Asp Ile Ala Lys Ser Val Tyr Ala Asn Thr Thr Asp Thr Ser Lys Phe Lys Glu Val Thr Ser Asn Met Ser Gly Asn Leu Asn Leu 400  
GAA GAC ATA GCG AAG AGT GTA TAT GCA AAT ACG ACA GAT ACT TCT AAA TTT AAA GAA GTC ACA AGT AAT ATG AGT GCG AAT TTG AAT TTA 1364

Gln Asn Asn Gly Ser Tyr Ser Leu Asn Ile Glu Asn Leu Asp Lys Thr Tyr Val Val His Tyr Asp Gly Glu Tyr Leu Asn Gly Thr Asp 430  
CAA AAT AAT GGA AGC TAT TCA TTG AAT ATA GAA AAT CTA GAT AAA ACT TAT GTT GTT CAC TAT GAT GGA GAG TAT TTA AAT GGT ACT GAT 1454

Glu Val Asp Phe Arg Thr Gln Met Val Gly His Pro Glu Gln Leu Thr Lys Thr Tyr Tyr Asp Arg Gly Tyr Thr Leu Thr Ser Asn 460  
GAA GTT GAT TTT AGA ACA CAA ATG GTA GGA CAT CCA GAG CAA CTT TAT AAG TAT TAT TAT GAT AGA GGA TAT ACC TTA ACT TGG GAT AAT 1544

Gly Leu Val Leu Tyr Ser Asn Lys Ala Asn Gly Asn Glu Lys Asn Gly Pro Ile Ile Gln Asn Asn Lys Phe Glu Tyr Lys Glu Asp Thr 490  
GGT TTA GTT TTA TAC AGT AAT AAA GCG AAC GGA AAT GAG AAA AAT GGT CCG ATT ATT CAA AAT AAT AAA TTT GAA TAT AAA GAT AAT ACA 1634

Ile Lys Glu Thr Leu Thr Gly Gln Tyr Asp Lys Asn Leu Val Thr Thr Val Glu Glu Glu Tyr Asp Ser Ser Thr Leu Asp Ile Asp Tyr 520  
ATT AAA GAA ACT CTT ACA GGT CAA TAT GAT AAG AAT TTA GTA ACT ACT GTT GAA GAG GAA TAT GAT TCA TCA ACT CTT GAC ATT GAT TAC 1724

His Thr Ala Ile Asp Gly Gly Gly Tyr Val Asp Gly Tyr Ile Glu Thr Ile Glu Glu Thr Asp Ser Ser Ala Ile Asp Ile Asp Tyr 550  
CAC ACA GCT ATA GAT GGT GGA GGT GGA TAT GTT GAT GGA TAT GTT GAT GAA AAT GAT ATT GAT ATT GAT ATT GAT ATT GAT ATT GAT 1814

His Thr Ala Val Asp Ser Glu Ala Gly His Val Gly Gly Tyr Thr Glu Ser Ser Glu Glu Ser Asn Pro Ile Asp Phe Glu Glu Ser Thr 580  
CAT ACT GCT JTG GAT AGC GAA GCA GGT CAC GTT GGA GGA TAC ACT GAG TCC TCT GAG GAA TCA AAT CCA ATT GAC TTT GAA GAA TCT ACA 1904

His Glu Asn Ser Lys His Ala Asp Val Glu Tyr Glu Glu Asp Thr Asn Pro Gly Gly Glu Val Thr Thr Glu Ser Asn Leu 610  
CAT GAA AAT TCA AAA CAT CAC GCT GAT GTT GTT GAA TAT GAA GAA GAT ACA AAC CCA GGT GGT GGT CAG GTT ACT ACT GAG TCT AAC TTA 1994

Val Glu Phe Asp Glu Glu Ser Thr Lys Gly Ile Val Thr Gly Ala Val Ser Asp His Thr Thr Val Glu Asp Thr Lys Glu Tyr Thr Thr 640  
GTT GCA TTT GAC GAA GAG TCT ACA AAA GGT ATT GTA ACT GGC GCA GTG AGC GAT CAT ACA ACA GTT GAA GAT ACG AAA GAA TAT ACA ACT 2084

Glu Ser Asn Leu Ile Glu Leu Val Asp Glu Leu Pro Glu Glu His Gly Gln Ala Gln Gly Pro Val Glu Glu Ile Thr Lys Asn Asn His 670  
GAA AGT AAT CTG ATT GAA TTA GTG GAT GAA TTA CCT GAA GAG CAT GGT CAA GCA CAA GGA CCA GTC GAG GAA ATT ACT AAA AAC AAT CAT 2174

His Ile Ser His Ser Gly Leu Gly Thr Glu Asn Gly His Gly Asn Tyr Asp Val Ile Glu Glu Ile Glu Glu Asn Ser His Val Asp Ile 700  
CAT ATT TCT CAT TCT GGT TTA GGA ACT GAA AAT GGT CAC GGG AAT ATT CAT GGT GAT ATT GAA GAA ATC GAA GAA AAT AGC CAA GAT GAT TAT 2264

Lys Ser Glu Leu Gly Tyr Glu Gly Gly Gln Asn Ser Gly Asn Gln Ser Phe Glu Glu Asp Thr Glu Glu Asp Lys Pro Lys Tyr Glu Gln 730  
AAG AGT GAA TTA GGT TAT GAA GGT GGC CAA AAT AGC GGT AAC CAG TCA TTC GAG GAA GAC ACA GAA GAA GAC AAA CCT AAA TAT GAA CAA 2354

Gly Gly Asn Ile Val Asp Ile Asp Phe Asp Ser Val Pro Gln Ile His Gly Gln Asn Lys Glu Asn Gln Ser Phe Glu Glu Asp Thr Glu 760  
GGT GGC AAT ATC GTA GAT AGT GAT TTT GAT AGT GTA CCT CAA ATT CAT GGT GAT CAA AAT AAA GGT AAT CAG TCA TTC GAG GAA GAT ACA GAA 2444

Lys Asp Lys Pro Lys Tyr Glu His Gly Gly Asn Ile Ile Asp Ile Asp Phe Asp Ser Val Pro His Ile His Gly Phe Asn Lys His Thr 790  
AAA GAC AAA CCT AAG TAT GAA CAT GGC GGT AAC ATC ATT GAT ATC GAC TTC GAC AGT GTG CCA CAT ATT CAC GGA TTC AAT AAG CAC ACT 2534

Glu Ile Ile Glu Glu Asp Thr Asn Lys Asp Lys Pro Ser Tyr Gln Phe Gly Gly His Asn Ser Val Asp Phe Glu Glu Asp Thr Leu Pro 820  
GAA ATT ATT GAA GAA GAT ACA AAT AAA GAT AAA CCA AGT TAT CAA TCA TTC GGT GGA CAC AAT AGT GTT GAC TTT GAA GAA GAT ACA CTT CCA 2624

Lys Val Ser Gly Gln Asn Glu Gly Gln Gln Thr Ile Glu Glu Asp Thr Thr Pro Pro Ile Val Pro Pro Thr Pro Pro Thr Pro Glu Val 850  
AAA GTA AGC GGC CAA AAT GAA GGT CAA CAA ACG ATT GAA GAA GAT ACA ACA CCT CCA ATC GTG CCA CCA ACG CCA CCG ACA CCA GAA GTG CCG GTA 2714

Pro Ser Glu Pro Glu Thr Pro Thr Pro Glu Val Pro Ser Glu Thr Pro Thr Pro Thr Pro Thr Pro Thr Pro Thr Pro Thr Pro Thr 880  
CCA AGT GAG CCG GAA ACA CCA ACG CCA CCA ACA CCA GAA-GTA CCA AGT GAG CCG GAA ACA CCA ACA CCA CCG ACA CCA GAA GTG CCG AGT 2804

Glu Pro Glu Thr Pro Thr Pro Thr Pro Glu Val Pro Ala Glu Pro Gly Lys Pro Val Pro Pro Ala Lys Glu Glu Pro Lys Lys Pro 910  
JAG CCA GAA ACT CCA ACA CCG CCA ACA CCA GAG GTA CCA GCT GAT AAA CCA GTA CCA CCT GCC AAA GAA GAA CCT AAA AAG CCT 2894

Ser Lys Pro Val Glu Gln Gly Lys Val Val Thr Pro Val Ile Glu Ile Asn Glu Lys Val Lys Ala Val Ala Pro Thr Lys Lys Pro Gln 940  
TCT AAA CCA GTG GAA CAA GGT AAA GTA GTA ACA CCT GTT ATT GAA ATC AAT GAA AAG GTT AAA GCA GTG GCA CCA ACT AAA AAA CCA CAA 2984

Ser Lys Lys Ser Glu Leu Pro Glu Thr Gly Gly Glu Glu Ser Thr Asn Lys Gly Met Leu Phe Gly Gly Leu Phe Ser Ile Leu Gly Leu 970  
TCT AAG AAA TCT GAA CTA CCT GAA GAG GGT GGA GAA GAA TCA ACA AAC AAA GGT ATG TTC GGC GGA TTA TTC AGC ATT CTA GGT TTA 3074

Ala Leu Leu Arg Arg Asn Lys Lys Asn His Lys Ala \*\*\* 982  
GCA TTA TTA CCG AGA AAT AAA AAG AAT CAC AAA GCA TAA TAAACAAAATTGACGGGTTTATTCATAAATTATATGAAAGTAAAGCTGTTTTTATATTAAATCAA 3181

ATTCTAATAGAAAATTAGAGTGTCTTCTGATTCCTTCTGATGATTAACGAACGAGATGAAGTTAGAAATTTAAACTAGT 3280

## Description

## A FIBRONECTIN BINDING PROTEIN AS WELL AS ITS PREPARATION.

## Technical field

5 The present invention relates to a fibronectin binding protein as well as hybrid-DNA-molecules, e.g. plasmids or phages comprising a nucleotide sequence coding for said protein. Further the invention relates to microorganisms comprising said molecules and their use producing said protein, as well as the synthetic preparation of said protein.

The object of the present invention is to obtain a minimal fibronectin binding protein.

10 A further object is to obtain said protein by means of a genetic engineering technique by using e.g. a plasmid comprising a nucleotide sequence coding for said protein.

A further object is to obtain a possibility of preparing said protein by chemical synthesis.

Further objects will be apparent from the following description.

## Background of the invention

WO-A1-85/05553 discloses bacterial cell surface proteins having fibronectin, fibrinogen, collagen, and/or laminin binding ability. Thereby it is shown that different bacteria have an ability to bind to fibronectin, fibrinogen, collagen, and/or laminin. It is further shown that fibronectin binding protein has a molecular weight of 165 kD and/or 87 kD, whereby it is probable that the smaller protein is a part of the larger one.

20 Fibronectin is a large glycoprotein ( $M_r$  ca 450 kD) with two similar subunits, which may vary in molecular size depending on a complex splicing pattern of a precursor mRNA (1). The major function of fibronectin, which is found in body fluids, blood clots and extracellular matrices, seems to be related to the ability of the protein to mediate substrate adhesion of most eukaryotic cells (2, 3, 4, 5.)

In the late seventies, Kuusela found that fibronectin not only interacts with eucaryotic cells but also binds to cells of *Staphylococcus aureus* (6). Since this observation, a number of pathogenic microorganisms have been shown to bind to fibronectin with a high degree of specificity and a high affinity (7). Fibronectin in the extracellular matrix appears to serve as a substratum also for the adhesion of different microorganisms. The binding of fibronectin may for some microorganisms represent a crucial step in the colonization of host tissue and development of infection.

30 Several different cell surface components have been implicated as fibronectin receptors on Gram-positive bacteria including lipoteichoic acid (8, 9) and protein (10). In previous studies a fibronectin binding protein with a  $M_r$  of 197-210 kD has been isolated from *S. aureus* strain Newman (11, 12) and tentatively identified as a fibronectin receptor. To further characterize this fibronectin binding protein from *S. aureus*, the gene for this protein has been cloned in *E. coli*. The fibronectin binding domain within this protein has also been localized and the behaviour of a fusin protein containing this domain and IgG-binding regions of protein A will be disclosed below.

## Description of the invention.

It has now surprisingly been found possible to obtain a hybrid-DNA-molecule comprising a nucleotide sequence coding for a protein or a polypeptide having fibronectin binding properties. As evident from below the following nucleotide sequence is present in the gene coding for said protein:

GGC CAA AAT AGC GGT AAC CAG TCA TTC GAG GAA GAC ACA GAA GAA GAC AAA CCT AAA TAT GAA  
 CAA GGT GGC AAT ATC GTA GAT ATC GAT TTT GAT AGT GTA CCT CAA ATT CAT GGT CAA AAT AAA GGT  
 AAT CAG TCA TTC GAG GAA GAT ACA GAA AAA GAC AAA CCT AAG TAT GAA CAT GGC GGT AAC ATC  
 45 ATT GAT ATC GAC TTC GAC AGT GTG CCA CAT ATT CAC GGA TTC AAT AAG CAC ACT GAA ATT ATT GAA  
 GAA GAT ACA AAT AAA GAT AAA CCA AGT TAT CAA TTC GGT GGA CAC AAT AGT GTT GAC TTT GAA GAA  
 GAT ACA CTT CCA AAA GTA AGC GGC CAA AAT GAA GGT CAA CAA AGC ATT GAA GAA GAT ACA ACA  
 CCT CCA ATC GTG CCA CCA ACG CCA CCG ACA CCA GAA GTA CCA AGT GAG CCG GAA ACA CCA ACG  
 CCA CCA ACA CCA GAA GTA CCA AGT GAG CCG GAA ACA CCA ACA CCA CCG ACA CCA GAA GTG CCG  
 50 AGT GAG CCA GAA ACT CCA ACA CCG CCA ACA CCA GAG GTA CCA GCT

The invention further comprises a plasmid or phage comprising a nucleotide sequence coding for said fibronectin binding protein.

The invention further comprises a microorganism comprising at least one hybrid-DNA-molecule according to the above.

55 The invention further comprises a method for producing a fibronectin binding protein whereby at least one hybrid-DNA-molecule of above is introduced into a microorganism, cultivating said microorganism in a growth medium, and isolating the protein thus formed by means of an affinity chromatography on a fibronectin bound to an insolubilized carrier followed by ion exchange chromatography.

60 A further aspect of the invention comprises a chemical synthesis of the fibronectin binding protein, whereby an amino acid sequence is built up based on said nucleotide sequence encoding for said protein starting from the C-terminal histidine which is stepwise reacted with the appropriate amino acid, whereby it is finally reacted with glycine at the N-terminal end, to form the fibronectin binding peptide region.

Appropriate carrier proteins can be coupled to the amino acid sequence as well, such as IgG binding

regions of protein A.

The invention will be described in the following with reference to the examples given, however, without being restricted thereto.

#### Example 1

##### Screening of a gene bank for fibronectin binding protein (FBNP)

A gene bank in plasmid pBR322 of chromosomal DNA from *Staphylococcus aureus* strain 8325-4 earlier described by (13) was screened for clones expressing FBNP. *E. coli* clones were lysed and the lysates were tested for their ability to inhibit the binding of  $^{125}\text{I}$ -fibronectin to cells of *S. aureus* Cowan I as described in the method section. To simplify screening the clones were pooled in lots of 25, lysed and tested. Out of the 22 pools tested, the one with the highest inhibitory activity was retested in 5 pools of 5. Finally, the individual clones in one positive pool were tested resulting in the isolation of one single positive clone. The plasmid in the positive clone was called pFR001.

This plasmid pFR001 in an *E. coli* strain 259 has been deposited at the Deutsche Sammlung von Mikroorganismen (DSM) and has thereby been allocated the deposition number 4124.

##### Isolation of the *Staphylococcal* FBNP from *E. coli* pFR001

The *E. coli* clone, positive for FBNP, was grown in LB-medium at 37°C to the stationary growth phase. The bacterial cells were centrifuged and lysed by an osmotic shock procedure (14). To exclude that inhibitory effect of the shock lysate on the binding of  $^{125}\text{I}$ -fibronectin to *S. aureus* cells is due to proteolytic activity, lysate was added to the incubation mixture and the amount of  $^{125}\text{I}$ -fibronectin bound to *S. aureus* was determined after 1, 2, 3, and 4 hrs of incubation. Throughout this incubation period, the level of inhibition caused by the lysate remained constant (e.g. 50%) suggesting that the observed inhibition was not due to a progressive degradation of the  $^{125}\text{I}$ -labelled ligand or corresponding receptor.

If the inhibitory activity is due to the presence of FBNP-like structures in the lysate, these should express a specific affinity for fibronectin. The lysate, was therefore analysed by affinity chromatography on a column of fibronectin-Sepharose as described in Materials and Methods (Fig. 1A). The purification was about 30 fold. Further fractionation was achieved by subjecting the affinity purified material to ion-exchange chromatography using a mono Q column fitted on to a FPLC-system. In this fractionation step two major peaks were obtained (Fig. 1B). Analyses by polyacrylamide gel electrophoresis indicated that the two peaks contained proteins of molecular weights 165 and 87 kD, respectively (Fig. 2). Both components inhibited the binding of  $^{125}\text{I}$ -fibronectin to *S. aureus*. The fraction containing the 165 kD protein had a specific inhibitory activity of 220 units/qg representing a 430-fold purification from the original shock lysate and it was 30 times more active than the 87 kD protein on a molar basis (data not shown).

Amino acid analysis of the two proteins showed that they had a very similar amino acid composition which also closely resembled that determined for the native FBNP isolated from *S. aureus* strain Newman (Table 1). The immunological relationship of 165 kD protein isolated from *E. coli* pFR001 to the native FBNP isolated from *S. aureus* strain Newman was analyzed. The 165 kD protein was  $^{125}\text{I}$ -labelled and immunoprecipitated with increasing dilutions of an antibody to *S. aureus* strain Newman. A 300-fold dilution of the antiserum precipitated 50% of the  $^{125}\text{I}$ -labelled protein. Unlabelled 165 and 87 kD proteins as well as the native FBNP interfered with the immunoprecipitation of the labelled 165 kD protein (data not shown). These observations suggest that the 165 and 87 kD proteins isolated from *S. aureus* strain Newman are closely related to fibronectin binding protein (FBNP).

##### Identification of the region of the *fnbp*-gene coding for the binding activity.

The size of the insert in plasmid pFR001 is about 6.5 kbp. The restriction map of the insert is shown in Fig. 3(A). In order to determine the transcription direction and to localize the region coding for the binding function, the *Pst*I fragment of about 3.7 kbp was recloned in the *Pst*I site of pBR322. This results in loss of the ampicillin resistance phenotype conferred by this plasmid. Eight such clones were obtained, five of which were positive and three negative for fibronectin binding activity. One of each was tested for the orientation of the *Pst*I fragment. The plasmid of the positive clone pFR004 had the *Eco*RI site closest to the Amp-promoter and that of the negative clone had the reverse orientation. These data indicated that the transcription orientation is from *Eco*RI to *Pst*I on the 3.7 kbp *Eco*RI - *Pst*I fragment and that at least a part of the *fnbp*-gene, which codes for the binding function, is located on this fragment. To verify this, the Amp-promoter in pFR004 was removed by *Eco*RI digestion followed by religation of the plasmid. The resulting plasmid pFR008 does not express fibronectin binding activity. In pFR001 the endogenous promoter is thus presumably located somewhere on the left hand side of the *Eco*RI site as indicated by the arrow in Fig. 3(A). By a plasmid construction (not described in detail here) the *Eco*RI (in the insert)-*Sal*I (in pBR322) fragment from pFR001 was introduced into pFR008. The fibronectin binding activity was then regained, due to the restoration of the endogenous promoter from the *fnbp*-gene.

Knowing the transcription direction of the *fnbp*-gene (from left to right as drawn in Fig. 3(A)) fusions were made to the gene for staphylococcal protein A. An expression/secretion vector called pRIT3 based on the protein A gene with restriction enzyme multilinker has been constructed (15). The multi-linker is placed immediately downstream of the last IgG-binding region, thus eliminating the C-terminal cellwall binding region

of protein A. The 3.7 kbp EcoRI-PstI fragment from pFR001 was inserted into this vector expecting it to encode a protein A-FNBP fusion protein, providing the reading frame was correct. This was obviously the case since the clone containing this plasmid, called pFR013, is positive in tests for both protein A and FNBP.

Plasmid pFR013 was treated with exonuclease Bal31 in order to identify a region smaller than the 3.7 kbp insert coding for the fibronectin binding activity. The plasmid was cleaved with EcoRI or PstI (at the 5' and the 3' end of the coding region, respectively), treated for various times with Bal31 and religated. During ligations a 20-fold excess of an EcoRI linker was added in order to introduce EcoRI sites at new positions. Fig. 3(C) shows the deletions obtained from either the 3' or the 5' end and the corresponding fibronectin binding activity. A region of the gene of about 700 bp coding for binding activity is located between the end points of deletions number 56 (deletion from the 5' end) and number 22 (deletion from the 3' end). From deletion plasmid number 56, the 900 bp region from the newly introduced EcoRI site to the PvuII site was subcloned. This fragment was cloned into pUC18 cleaved with EcoRI and SmaI. The resulting plasmid, which encodes a fusion protein with both  $\beta$ -galactosidase and fibronectin binding activity, is called pFR015. The fragment can be recloned from pFR015 by EcoRI and BamHI cleavages because of the multilinker in pUC18.

Restriction fragments were also subcloned as indicated in Fig. 3(B). In the case of EcoRI-PstI and EcoRI-Clal fragments the protein A expression vector pRIT3 was used. Fragments Bal-PvuII and Bal-HincII were subcloned and expressed in pUC18. In all cases, except for the EcoRI-Clal fragment, fusion proteins with fibronectin binding activity were obtained. The negative result in the case of the Clal-Clal subclone may be due to the insert appearing in the wrong reading frame.

#### Production and characterization of a fusion protein, ZZ-FR

The yield of the 165 kD protein (Fig.2) from an osmotic shock lysate of *E. coli* HB101 cells carrying the plasmid pFR001 was approximately 40  $\mu$ g per liter culture medium. Even if there were losses due to degradation of the high molecular weight compound during the purification all data indicated that the *fnbp*-gene with the endogenous promoter is weakly expressed in *E. coli*. In order to improve the level of expression we used a recently developed expression system, which allows heterologous proteins to be secreted to the growth medium of *E. coli* (16). The plasmid vector used, pEZZ318, contains two synthetic, slightly modified IgG-binding domains of the gene for staphylococcal protein A preceded by the promoter and signal sequence of the same gene. A Bal-PvuII fragment of approximately 600 bp of the *fnbp*-gene (Fig. 3(B)) cloned in pUC18 was recloned into pEZZ318 cleaved with EcoRI and HindIII. After ligation and transformation pEZZ-FR was isolated. This plasmid encodes a fusion protein consisting of the IgG binding product ZZ and a fibronectin binding region FR of the FNBP.

For production of the ZZ-FR protein *E. coli* strain HB101 carrying the plasmid pEZZ-FR was grown overnight in Trypticase Soy Broth. Bacteria were removed by centrifugation and the growth medium was passed through an IgG-Sepharose Fast Flow column. After washing the column with TST-buffer (50 mM Tris-HCl pH 7.4 150 mM NaCl, 0.05% Tween<sup>R</sup> 20) the ZZ-FR protein was eluted with 0.5 M acetic acid titrated to pH 2.8 using ammonium acetate. Approximately 50 mg protein was eluted from the column per liter of growth medium applied.

After lyophilization the eluted material was analyzed by SDS-PAGE, which revealed a major protein band at approximately 63 kD (Fig. 4). In addition, bands corresponding to smaller fragments appeared, probably due to proteolytic degradation of the fusion protein. The intact protein A which was run on the same gel appeared as a diffuse band around 56 kD. The proteins in the gel were electrophoretically transferred to a nitrocellulose paper and probed with a <sup>125</sup>I-labelled 29 kD fibronectin fragment. Fig. 4, lanes C and D, shows that the fusion protein but not intact protein A, binds the radiolabelled fibronectin fragment.

Further evidence for the fibronectin binding ability of the ZZ-FR fusion protein was obtained by affinity chromatography on a Sepharose column substituted with the 29 kD fibronectin fragment. The fusion protein was bound to the column and was eluted from the affinity matrix with 6M GuHCl (Fig. 5A). The fibronectin binding activity of the ZZ-FR fusion protein was apparently located in the FR-region since intact protein A did not bind to the affinity matrix (Fig. 5B). The portion of the ZZ-FR fusion protein preparation that did not bind to the affinity matrix consisted of proteins with *M<sub>r</sub>* lower than of the intact fusion protein (Fig. 6, lane A) whereas the material binding to the column consisted of an almost pure preparation of intact 63 kD ZZ-FR fusion protein (Fig. 6, lane B).

In order to determine how much of the fibronectin binding capacity of staphylococcal cells that can be ascribed to the cloned FNBP, the inhibitory activity of the fusion protein ZZ-FR was quantified. As shown in Fig. 7 the fusion protein totally inhibited the binding of <sup>125</sup>I-labelled 29 kD fragment as well as intact fibronectin to cells of both *S. aureus* strains Newman and 8325-4, protein A, which was used as a control, did not inhibit the binding (Fig. 7).

After the report by Kuusela (6) that *S. aureus* binds to fibronectin much work has been focused on attempts to identify the bacterial component(s) responsible for the binding. The rationale for these studies has been that binding of pathogenic bacteria to fibronectin may represent a mechanism of tissue adherence of crucial importance in the early stages of an infection. Proteins purified by affinity chromatography on immobilized fibronectin, have been implicated in the binding of staphylococcal cells to fibronectin. However the reported molecular weights of the fibronectin binding proteins vary from 18 kD (10) all the way up to 197 and 210 kD (11, 17). The main reason for the heterogeneity in molecular size may be proteolytic degradation of the proteins during the isolation procedures.

In the present disclosure the cloning in *E. coli* of a gene coding for a fibronectin binding protein from *S. aureus* strain 8325-4 is disclosed. When the *fnbp*-gene is expressed in *E. coli* from the endogenous promoter the protein can be isolated from the periplasm by osmotic shock. This indicates that not only the promoter but also the signal peptide is functional in *E. coli*.

Although the proteins coded for by the cloned *fnbp*-gene have molecular weights of 165 and 87 kD (Fig. 2), which is smaller than the FNBP isolated from *S. aureus* strain Newman ( $M_r=210$ kD) (12), their amino acid compositions closely resemble that of the native protein (Table 1). Furthermore, antibodies raised against the native FNBP cross-react with the 165 and 87 kD proteins. These data strongly suggest that the structure of the proteins coded for by the cloned gene from *S. aureus* strain 8325-4 resembles that of native FNBP from *S. aureus* strain Newman. The 87 kD protein may be the result of pretermination at the transcriptional or translational level or alternatively proteolytic cleavage of the 165 kD protein. At present it cannot be explained why the 165 kD protein is as much as 30 times more active than the 87 kD protein in inhibition of fibronectin binding to *S. aureus* cells.

By deletion mapping using *Bal*31-cleavage and subcloning of restriction fragments the domain of the *fnbp*-gene encoding the fibronectin binding activity had been located to a region of approximately 350 bp (Fig. 3(B)). A fragment of the gene of approximately 600 bp covering these 350 bp was ligated directly to a tandemly repeated sequence (ZZ) of a synthetic IgG-binding domain of the protein A gene preceded by the protein A promoter and signal sequence in expression vector pEZZ318 (16). The resulting fusion protein (ZZ-FR), which has a molecular weight of approximately 63 kD as determined by SDS-PAGE (Fig. 4), contains 126 amino acids of the ZZ domain followed by approximately 200 amino acids encoded by the 600 bp insert from the *fnbp*-gene. The C-terminal end of the protein consists of amino acids which are the result of an out of frame read-through into the *lacZ'* gene of the vector until a translation stop codon is reached. The fusion protein (ZZ-FR), which is expressed at a high level and secreted to the growth medium of *E. coli*, is easily isolated by affinity chromatography making use of the IgG-binding ability of the ZZ-domain.

The ZZ-FR protein was bound to the 29 kD NH<sub>2</sub>-terminal domain of fibronectin and completely inhibited the binding of intact fibronectin to *S. aureus* (Figs. 5 and 6). These data indicate that under the incubation conditions used other proteins, recognizing domains outside the 29 kD N-terminus of fibronectin, are not expressed by the staphylococcal cells. Furthermore the fibronectin binding activity of the FNBP has been localized to a fairly small segment of the protein. Recent analysis of the native 210 kD FNBP isolated from *S. aureus* strain Newman demonstrated that this protein is multivalent and one molecule of the FNBP is capable of binding 6-9 fibronectin molecules (12). The cloned *fnbp*-gene is derived from strain *S. aureus* 8325-4. If there are no differences between strains of *S. aureus* one would expect the FR-region to contain several repeating sequences. This question was also answered by sequence analysis of the cloned *fnbp*-gene. The sequence of the FR-region having FNBP-properties is given in Fig. 8.

There is reason to believe that the FR binding activity is related to the each of the three 38 amino acids repeats as the *Bal*1-PvuII-fragment encodes for a binding activity (cf. Fig. 3); as the *Bal*1-HincII-fragment encodes for a binding activity; and as the *Hinc*II-PvuII-fragment does not encode for binding activity. Furthermore, the one single 38 amino acids repeat is functional in binding fibronectin, since a synthesized 38-amino acids long peptide (38(2)-repeat) has binding ability, as shown in Fig. 9. Each of the three 38 amino acids repeats are very homologous.

## Example 2.

Chemical synthesis of a polypeptide based on the nucleotide sequence coding for the fibronectin binding domain of 38 amino acids (38(2) repeat) was performed by building up the amino acid sequence corresponding to said nucleotide sequence starting from the C-terminal histidine and stepwise reacting with the appropriate amino acid and finally reacting with the glycine at the N-terminal end, in a solid phase synthesis according to the method by K.B. Merrifield, J. Am. Chem. Soc. 86, pp.304, (1964). Hereby the polypeptide corresponding to the second 38 amino acid repeat was synthesized, as well as three further polypeptides being parts of this 38-repeat, viz: 1) the polypeptide covering amino acids 1-19, 2) the polypeptide covering amino acids 9-30, and 3) the polypeptide covering amino acids 20-38, were all synthesized according to the same method.

The fibronectin binding ability of the complete 38-repeat, as well as of the 1-19 amino acid polypeptide, the 9-30 amino acid polypeptide, the 20-38 amino acid polypeptide, as well as a mixture of these three smaller polypeptides was tested, and the result is given in Fig. 9. The fragments of the complete 38-repeat were synthesized in order to check if fibronectin binding is dependent upon the complete 38-repeat, as anticipated, or if fibronectin binding properties could be further confined to some smaller region of the 38 amino acid sequence. As evident from Fig. 9 the fibronectin binding property is only present in the complete 38 amino acids peptide.

## MATERIALS AND METHODS

**Bacterial strains and plasmids.** A gene bank in pBR322 of chromosomal DNA from *Staphylococcus aureus* strain 8325-4, earlier described (13) was screened for clones expressing fibronectin binding activity. *E. coli* strains HB102, (18) and JM105 (19), were used in subcloning and expression experiments. The plasmid vectors used were pBR322 (20) pUC18 (21) and the protein A vectors pRIT3 (15) and pEZZ318 (16). *S. aureus* strains Cowan I, Newman and 8325-4 were used in the assay of the fibronectin binding protein (FNBP).

Microorganism growth medium. At the culture of *E. coli* bacteria the following medium was used. The amounts given relates to 1 litre of medium.

Trypton Soy Broth (Oxoid Ltd, Basingstoke, Hants, GB) 30 g

Yeast Extract (Oxoid) 10 g

5 D-glucose 40 g

NH<sub>4</sub>Cl 2,5 g

Na<sub>2</sub>HPO<sub>4</sub>·2H<sub>2</sub>O 7,5 g

KH<sub>2</sub>PO<sub>4</sub> 3,0 g

Na<sub>2</sub>SO<sub>4</sub>·10H<sub>2</sub>O 2,5 g

10 MgSO<sub>4</sub>·7H<sub>2</sub>O 0,2 g

CaCl<sub>2</sub>·2H<sub>2</sub>O 0,5 mg

FeCl<sub>3</sub>·6H<sub>2</sub>O 16,7 mg

ZnSO<sub>4</sub>·7H<sub>2</sub>O 0,18 mg

CuSO<sub>4</sub>·5H<sub>2</sub>O 0,16 mg

15 MnSO<sub>4</sub>·4H<sub>2</sub>O 0,15 mg

CoCl<sub>2</sub> 0,10 mg

NaEDTA 20,1 mg

Assay of fibronectin binding protein (FBNP). Quantitation of fibronectin binding to cells of *S. aureus* has been described earlier (10). If not otherwise stated, 10<sup>9</sup> cells of *S. aureus* Cowan I are incubated with <sup>125</sup>I-labelled fibronectin or the 29 kD NH<sub>2</sub>-terminal fragment of fibronectin in PBS containing 1 mg/ml bovine serum albumin in a total volume of 0,3 ml. After incubation for 2 hours at 22°C the radioactivity bound to the cells is measured in a gamma counter.

Lysates of *E. coli* clones prepared in Tris-HCl buffer, pH 8,1, containing lysozyme EDTA as earlier described (13), were analysed for fibronectin binding activity by measuring their ability to compete with staphylococcal cells for binding the <sup>125</sup>I-labelled 29 kD NH<sub>2</sub>-terminal fragment of fibronectin. The amount of FBNP able to inhibit binding to 50% is considered as one unit of activity.

An osmotic shock procedure was used to release proteins from the periplasmic space of *E. coli* (14).

Purification of FBNP. The purification is based on affinity chromatography on fibronectin-Sepharose followed by ion-exchange chromatography.

Human fibronectin was prepared from outdated blood by the method known (22). The fibronectin was then dialysed against 20 mM Tris-HCl, pH 8,3 and concentrated on a DEAE-column. The coupling of fibronectin to Sepharose SL-4B was done by a bromocyan activation procedure as known (23).

The *E. coli* lysate was pumped onto the affinity column which was subsequently washed with 0,5 M ammonium acetate until the baseline was stable (about four column volumes). The FBNP was then eluted with 0,4M acetic acid and either neutralized with ammonia or lyophilized. After dialysis against 10 mM ammonium acetate with pH adjusted to 7,6 with ammonia a further fractionation step was performed by ion-exchange chromatography on a Pharmacia FPLC equipment using a mono Q column.

Nucleotide sequence analysis. The nucleotide sequence was determined in accordance with the methods described by Maxam, A.M. et al (27).

Amino acid analysis. The amino acid composition was determined using a Durrum D-500 analyzer. Samples were hydrolyzed in 6 M HCl containing 2 mg/ml phenol for 24 hours at 1100°C. One sample was also oxidized with performic acid in order to determine cysteine and methionine. Norleucine was added as an internal standard. Protein was determined according to (24) using bovine serum albumin as a standard.

Electrophoresis. If not indicated otherwise SDS-polyacrylamide gel electrophoresis was performed in 5-15% gradient gels. The gels were stained with Coomassie brilliant blue, de-stained and photographed.

Radioimmunoassay procedure. The purified FBNP with an estimated molecular weight in SDS-polyacrylamide gel electrophoresis of 165 kD was labelled with <sup>125</sup>I-iodine by the chloramine-T method as known (25). After the iodination the material was rechromatographed on a fibronectin-Sepharose column.

The incubation mixture contained <sup>125</sup>I-FBNP (3 400 cpm in 10 µl) was mixed with various dilutions of a rabbit antiserum (containing antibodies directed against *S. aureus* strain Newman), in incubation buffer (PBS, 0,1% Triton X-100 and 0,02% sodium azide) in a volume of 0,2 ml.

Samples were incubated for 2 hours at 20°C to allow antigen-antibody reaction. 0,1 ml of 10% suspension (w/v) of protein A-Sepharose in PBS was added and the mixture was incubated for another hour. The incubation was stopped by adding another 1,7 ml of incubation buffer to the samples. After centrifugation at 2000 rpm for 3 min the supernatants were sucked off. The pellets were washed twice in incubation buffer and the radioactivity associated with the protein A-Sepharose was measured in a gammacounter.

Restriction endonucleases and other enzymes. Restriction enzymes, T4 DNA ligase and Bal31 were purchased from BRL and used according to their recommendations. Other methods involving DNA techniques were essentially as known (26).

Amino acid	Composition (mol%)		
	210kd <sup>a)</sup>	165 kd	87 kd
Aspartic acid/asparagine	15.4	14.6	13.4
Threonine	9.7	10.7	10.3
Serine	7.4	6.5	8.0
Glutamic acid/glutamine	17.9	17.1	15.1
Proline	6.3	6.2	5.8
Glycine	8.9	7.9	8.4
Alanine	5.3	4.6	4.7
Half-cystine	0.1	0.2	n.d.
Valine	7.2	7.8	8.6
Methionine	0.6	0.6	n.d.
Isoleucine	4.3	4.7	3.8
Leucine	4.1	4.0	4.6
Tyrosine	2.1	2.3	4.1
Phenylalanine	2.4	2.0	3.6
Histidine	1.0	3.2	3.0
Lysine	5.3	6.3	6.6
Tryptophan	n.d.	n.d.	n.d.
Arginine	1.9	1.2	-

a) from Fröman et al.(1987), (12).

n.d.= not determined



The present fibronectin binding protein can be used for immunization, whereby the protein, preferably in combination with a fusion protein to create a large antigen to respond to, is injected in dosages causing immunological reaction in the host mammal. Thus the fibronectin binding protein can be used in vaccination of ruminants against mastitis caused by Staphylococcal infections. The fibronectin binding protein of this invention has shown to form antibodies against a staphylococcal mastitis in a mouse model as shown in the Table below.

TABLE

Experimental mouse mastitis produced by S. aureus strain SA 113(83A) in a dose of  $1.0 \times 10^3$  cfu. Evaluation of immunization using 15  $\mu$ g protein per mouse of the fibronectin binding protein expressed from E. coli containing plasmid pFR001 as identified herein.

Group of mice	No. of mammary glands inocul.	Gross examination type of lesion(%)				No. of mammary glands invest.	Microscopic type of lesion(%)				
		+++	++	+	0		A	B	C1	C2	C3
Vaccinated (FNBP)	30	3	8	83	10	11	9	0	0	91	0
Control	38	50	16	32	3	8	38	0	25	38	0

Mastitis: +++ = gross; ++ = medium-grade; + = low grade; 0 = no macroscopic changes;

A = consistently non-reactive, total necrosis; B = advanced regressive changes + slight inflammatory reaction; C1 = disseminated inflammatory reaction + local necrosis; C2 = disseminated inflammatory reaction; C3 = local inflammatory reaction; 0 = no reaction.

As evident from the Table above a consistent immunization is obtained using the FNBP as expressed by the E. coli containing the plasmid pFR001.

Further, the fibronectin binding protein can be used to block an infection in an open skin wound by wound treatment using the fibronectin binding protein in a suspension. Thus the fibronectin binding protein can be used for the treatment of wounds, e.g. for blocking protein receptors, or for immunization (vaccination). In the latter case the host body produces specific antibodies, which can protect against invasion of bacterial strains comprising such a fibronectin binding protein. Hereby the antibodies block the adherence of the bacterial strains to damaged tissue.

Examples of colonizing of a tissue damage are:

a) colonizing of wounds in skin and connective tissue, which wounds have been caused by a mechanical trauma, chemical damage, and/or thermal damage;

b) colonizing of wounds on mucous membranes, such as in the mouth cavity, or in the mammary glands, urethra, or vagina;

c) colonizing on connective tissue proteins, which have been exposed by a minimal tissue damage (microlesion) in connection with epithellum and endothellum (mastitis, heart valve infection, hip exchange surgery).

When using the present FNBP, or the 38 amino acid polypeptide, for the purpose of immunization (vaccination) in mammals, including man, the protein, or polypeptide is dispersed in sterile, isotonic saline solution, optionally while adding a pharmaceutically acceptable dispersing agent. Different types of adjuvants can further be used in order to sustain the release in the tissue, and thus expose the protein or the peptide for a longer time to the immunodefense system of a body.

A suitable dosage to obtain immunization is 0,5 to 5 µg of FNBP, or polypeptide, per kg bodyweight and injection of immunization. In order to obtain a durable immunization, vaccination should be carried out at more than one consecutive occasions with an interval of 1 to 3 weeks, preferably at three occasions.

When using the present FNBP, or polypeptide, for topical, local administration the protein is dispersed in an isotonic saline solution to a concentration of 25 to 250 µg per ml. The wounds are then treated with such an amount only to obtain a complete wetting of the wound surface. For an average wound thus only a couple of millilitres of solution are used in this way. After treatment using the protein solution the wounds are suitably washed with isotonic saline or another suitable wound treatment solution.

Further the fibronectin binding protein as well as the minimal fibronectin binding site polypeptide, of the present invention can be used to diagnose bacterial infections caused by Staphylococci strains, whereby a fibronectin binding protein of the present invention is immobilized on a solid carrier, such as small latex or Sepharose<sup>®</sup> beads, whereupon sera containing antibodies are allowed to pass and react with the FNBP thus immobilized. The agglutination is then measured by known methods.

Further, the FNBP, or the polypeptide can be used in an ELISA test (Enzyme Linked Immuno Sorbent Assay; E Engvall, Med. Biol. 55, 193, (1977)). Hereby wells in a polystyrene microtitre plate are coated with the FNBP, and incubated over night at 4°C. The plates are then thoroughly washed using PBS containing 0.05% TWEEN 20, and dried. Serial dilution of the patient serum were made in PBS-Tween, were added to the wells, and incubated at 30°C for 1.5 hrs. After rinsing antihuman-IgG conjugated with an enzyme, or an antiovine-IgG conjugated with an enzyme, respectively, horseradishperoxidase or an alkaline phosphatase, was added to the wells and incubated at 30°C for 1,5 hrs, whereupon when the IgG has been bound thereto, and after rinsing, an enzyme substrate is added, a p-nitrophosphate in case of an alkaline phosphatase, or orthophenylene diamine substrate (OPD) in case a peroxidase has been used, respectively. The plates comprising the wells were thus then rinsed using a citrate buffer containing 0.055% OPD, and 0.005% H<sub>2</sub>O<sub>2</sub>, and incubated at 30°C for 10 min. Enzyme reaction was stopped by adding a 4N solution of H<sub>2</sub>SO<sub>4</sub> to each well. The colour development was measured using a spectrophotometer.

Depending on the type of enzyme substrate used a fluoroscense measurement can be used as well.

Another method to diagnose Staphylococci infections is by using the DNA gene probe method based on the FNBP sequence or the 38 amino acid polypeptide sequence. Thereby the natural or synthetic DNA sequences are attached to a solid carrier, such as a polystyrene plate as mentioned above, by e.g. adding a milk in the case of diagnosing a mastitis, to the surface. The DNA gene probe, optionally labelled enzymatically, or by a radioactive isotope is then added to the solid surface plate comprising the DNA sequence, whereby the DNA gene probe attaches to the sequence where appearing. The enzyme or the radioactive isotope can then readily be determined by known methods.

Above the term fibronectin binding protein includes any of the 38 amino acid polypeptide sequences as well, which 38 amino acid polypeptide sequences forms the minimal fibronectin binding site of the complete protein.

REFERENCES 8. Beachey, E.H. and Simpson, W.A.(1982). Infection 10, 107-110.

20. Bolivar, F., Rodriguez, R.L., Greene, P.J., Betlach, M.C., Heyneker, H.L., Boyer, H.W., Crosa, J.H. and Falkow, S. (1977). Gene, 2, 95-113.

18. Boyer, H.W. and Roulland-Dussoix, D. (1969). J. Mol.Biol: 41, 459-472.

9. Courtney, H.S., Ofek, I., Simpson, W.A., Hasty, D.L. and Beachey, E.H. (1986). Infect. Immun. 53 454-459.

11. Espersen, F. and Clemmensen, I. (1982). Infect. Immun. 37, 526-531.

17. Fröman, G., Switalski, L.M., Guss, B., Lindberg, M., Höök,

M. and Wadström, T. (1986) In Lark, D.L. ed. Protein-Carbohydrate Interactions in Biological Systems. Academic Press, London, pp. 263-268.

12. Fröman, G., Switalski, L.M., Speziale, P. and Hook, M. (1987) In press. J. Biol. Chem.

25. Hunter, W.M. (1978) Radioimmunoassay. In: Wier, K.M. ed. Handbook of Experimental Immunology. London Blackwell. 14.1-14.40.

1. Hynes, R.O. (1985) Annu. Rev. Cell Biol. 1, 67-90.

2. Hynes, R.O. (1986) Sci. Ann. 254, 42-51.

6. Kuusela, P. (1978) Nature 276, 718-720.

24. Lowry, O.H., Rosebrough, N.J., Farr, A.L. and Randall, R.J., Biol. Chem. 193, 265-275.

13. Löfdahl, S., Guss B., Uhlén, M., Philipson, L. and Lindberg, M. (1983) Proc. Natl. Acad. Sci. USA 80, 697-701.

26. Maniatis, T., Fritsch, E.F. and Sambrook, J. (1982). Molecular cloning: a laboratory manual, Cold Spring Harbor Laboratory, New York.

23. March, S.C., Parikh, I. and Cuatrecasas, P. (1974). *Analyt. Biochem.* **60**, 149-152.
27. Maxam, A.M. and Gilbert, W., (1977), *Proc. Natl. Acad. Sci., USA*, **74**, 560.
28. Merrifield, K.B., *J. Am. Chem. Soc.*, **86**, pp.304, (1984)
19. Messing, J. and Carlsson, J. (1984). *J. Biotechnol.* **1**, 253-264.
- 5 22. Miekka, S.I., Ingham, K.C. and Menache, D. (1982). *Thromb Res.* **27**, 1-14.
15. Nilsson, B., Abrahamsén, I. and Uhlén, M. (1985). *EMBO J.* **4**, 1075-1080.
16. Nilsson, B., Moks, T., Jansson, B., Abrahamsén, L., Elmblad, A., Holmgren, E., Henrichson, L., Jones, T.A. and Uhlén, M. (1986). *Protein Engineering*, In press.
21. Norrander, J., Kempe, T. and Messing, J. (1983). *Gene*, **26**, 101-106.
- 10 14. Nossal, N.G. and Heppel, L.A. (1965). *J. Biol. Chem.* **241**, 3055-3062.
3. Ruoslahti, E. and Pierschbacher, M.D. (1986). *Cell*, **44**, 517-518.
10. Rydén, C., Rubin, K., Speziale, P., Höök, M., Lindberg, M. and Wadström, T. (1983), *J. Biol. Chem.* **258**, 3396-3401.
7. Wadström, T., Switalski, L., Speziale, P., Rubin, K., Rydén, C., Fröman, G., Faris, A., Lindberg, M., Höök, M., (1985), In Jackson, G.J. (ed), *Pathogenesis of Infection*. Springer Verlag, Berlin, Heidelberg, New York, Tokyo, pp. 193-207.
- 15 4. Woods, A., Couchman, J.R., Johansson, S., and Höök, M. (1986), *EMBO J.* **5**, 665-670.
5. Yamada, K.M. (1983), *Annu. Rev. Biochem.* **52**, 761-799.

## 20 LEGENDS TO THE FIGURES

### Fig. 1A. Affinity chromatography on fibronectin-Sepharose

A lysate (86 ml) obtained by cold osmotic shock of the *E. coli* clone pFR001 was mixed with 29 ml of 2 M ammonium acetate. The sample was then applied to a column (1.9 x 5.7 cm) equilibrated with 0.5 M ammonium acetate at a flow rate of 50 ml/h. After the application of the sample the column was washed with four column volumes of 0.5 M ammonium acetate at a flow rate of 20 ml/h. At the same time the sensitivity of the UV-monitor was increased by a factor of five. The material eluting between 200 and 220 ml was pooled, neutralized with ammonium hydroxide and dialysed against 10 mM ammonium acetate, pH 7.6.

### 30 Fig. 1B. Ion-exchange chromatography

A sample (10 ml) of the dialysed material from the affinity-chromatography described in Fig. 1A was applied to a 1ml Mono Q (Pharmacia, Sweden) anion column equilibrated with 10 mM ammonium acetate, pH 7.6. The flow rate was 2 ml/min and the column was eluted by a linear increase in the concentration of ammonium acetate of 25 mM per ml. The two peaks (I and II) were pooled as indicated in the figure.

### 35 Fig. 2. Polyacrylamide gel electrophoresis of materials from the different purification steps of an osmotic shock lysate of *E. coli* pFR001

Material applied (lane 1) to the affinity column (fibronectin-Sepharose), unadsorbed (lane 2) and adsorbed (lane 3) material. Ion exchange chromatography of affinity purified material on a Mono Q FPLC column (Pharmacia, Sweden): pool I (lane 4) and pool II (lane 5) as marked in Fig. 1B.

### Fig. 3. Restriction map, subclones and deletions of the insert in pFR001

(A) Restriction map of the 6.5 kb insert. (B) various subclones constructed in order to determine the region of the gene which codes for the fibronectin binding activity. (C) Deletions made from either the 3' or the 5' end of the *EcoRI*-*PstI*-fragment by treatment with exonuclease *Bal31* (see text for details). The fibronectin binding activity for the different gene products is indicated.

### Fig. 4. Polyacrylamide gel electrophoresis of the ZZ-FR pro-teín

Protein A (Sigma Chemical Co, St. Louis; lane A) and the ZZ-FR fusion protein (lane B) were reduced and subjected to electrophoresis in SDS on a 5-15% polyacrylamide gel. The gel was subsequently stained with Coomassie blue. In lanes C & D the ZZ-FR fusion protein and protein A, respectively, were fractionated by SDS-electrophoresis on a 5-9% polyacrylamide gel, electroblotted to nitrocellulose paper and probed with <sup>125</sup>I-labelled 29 kD fibronectin fragment as described (Fröman et al, 1987). Arrows indicate the migration distance of standard proteins of known molecular weights.

### Fig. 5. Affinity chromatography of the ZZ-FR protein

The ZZ-FR fusion protein (0.6 mg; panel A) and protein A (Sigma Chemical Co; 0.5 mg; panel B) were applied to a 7 ml column of Sepharose 4B CL substituted with 29 kD fibronectin fragment. The column was washed with 0.5 M NaCl in PBS and subsequently eluted with 6 M GuHCl in PBS. Fractions of 2 ml were collected and assayed for protein using the BioRad system.

### Fig. 6. Polyacrylamide gel electrophoresis of the ZZ-FR fusion protein preparation, fractionated by affinity chromatography.

Material not bound (lane A) and bound and eluted (lane B), respectively, from the 29 kD affinity column was analyzed by SDS-gel electrophoresis on 5-15% polyacrylamide gels. The gel was subsequently stained with

Coomassie blue. Arrows indicate the migration distance of standard proteins of known molecular weights.

**Fig. 7. Inhibition of binding  $^{125}$ I-fibronectin to bacterial cells.**

Staphylococcal cells ( $5 \times 10^7$ ) of strain Newman (panel A) or strain 8325-4 (panel B) were incubated with  $5 \times 10^4$  cpm of  $^{125}$ I-labelled intact fibronectin (o-o) or 29 kD N-terminal fibronectin fragment ( $\Delta$ - $\Delta$ ) in PBS supplemented with 0.1% BSA, and 0.1% Tween<sup>R</sup> 80 in a total volume of 0.5 ml for 1 hr in the presence of increasing amounts of ZZ-FR fusion protein or protein A (●-●). For further details of the binding assay used, see Fröman et al (1987). The amounts of  $^{125}$ I-radioactivity associated with bacterial cells was quantitated and the extent of fibronectin binding calculated. One hundred percent binding represent  $^{125}$ I-ligand bound to bacteria in absence of inhibiting protein and 0% binding corresponded to radioactivity recorded from incubation mixtures without bacteria.

**Fig. 8A. Sequence of nucleotide coding for fibronectin binding protein.**

The nucleotide sequence coding for the fibronectin binding protein together with its corresponding amino acids is given. The different 38-amino acids repeats are marked, as well as appearing following almost four complete 14 amino acids repeats. The restriction sites Ball-HincII-Pvull have been noted in the figure, as well as have the amino acids sequences corresponding to the different nucleotide sequences.

**Fig. 9 The fibronectin binding ability of a chemically synthesized polypeptide.**

The fibronectin binding ability of the chemically synthesized 38 amino acids polypeptide according to Example 2 together with the fibronectin binding ability of the fragments of said polypeptide have been tested. (\*-\*) denotes the polypeptide corresponding to the 38(2) repeat of the amino acids sequence; (\*-\*) denotes the polypeptide corresponding to amino acids 1-19 of the amino acids sequence; (o-o) denotes the polypeptide corresponding to amino acids 20-38 of the amino acids sequence; ( $\Delta$ - $\Delta$ ) denotes the polypeptide corresponding to amino acids no. 9-30 of the amino acids sequence; and (- -) the polypeptide mixture comprising the polypeptides of amino acids 1-19, amino acids 20-38, amino acids 9-30. The binding ability in percent has been plotted against  $\mu$ g of polypeptide added.

## Claims

1. Hybrid-DNA-molecule comprising a nucleotide sequence from S. aureus coding for a protein or polypeptide having fibronectin binding ability.
2. Plasmid or phage comprising a nucleotide sequence from S. aureus coding for a protein or a polypeptide having fibronectin binding ability.
3. A plasmid pFR001 as contained in the E. coli strain 259 having the deposit number DSM 4124.
4. An E. coli strain expressing said fibronectin binding protein.
5. A microorganism transformed by recombinant DNA molecule of claims 1-3.
6. Hybrid-DNA-molecule according to claim 1, characterized in that it comprises one or more of the following nucleotide sequences

GGC CAA AAT AGC GGT AAC CAG TCA TTC GAG GAA GAC ACA GAA GAA GAC AAA CCT AAA TAT  
GAA CAA GGT GGC AAT ATG GTA GAT ATC GAT TTT GAT AGT GTA CCT CAA ATT CAT

GGT CAA AAT AAA GGT AAT CAG TCA TTC GAG GAA GAT ACA GAA AAA GAC AAA CCT AAG TAT  
GAA CAT GGC GGT AAC ATC ATT GAT ATC GAC TTC GAC AGT GTG CCA CAT ATT CAC

GGA TTC AAT AAG CAC ACT GAA ATT ATT GAA GAA GAT ACA AAT AAA GAT AAA CCA AGT TAT CAA  
TTC GGT GGA CAC AAT AGT GTT GAC TTT GAA GAA GAT ACA CTT CCA AAA GTA

7. Plasmid or phage comprising one or more nucleotide sequences according to claim 6.
8. Microorganism containing at least a plasmid or phage according to claim 7.
9. A method for producing a fibronectin binding protein or polypeptide, wherein a) at least one hybrid-DNA-molecule according to claim 1 is introduced into a microorganism, b) said microorganism is cultivated in a growth promoting medium, and c) the protein thus formed is isolated by means of an affinity chromatography on a column with fibronectin bound to an insolubilized carrier followed by ion exchange chromatography.
10. A chemical synthesizing method for producing a fibronectin binding protein or polypeptide according to claim 1, whereby an amino acid residue is built up based on said nucleotide sequence encoding for said protein or polypeptide, starting from the C-terminal histidin, which is stepwise reacted with the appropriate amino acid, whereby it is finally reacted with glycine at the N-terminal end, to form the fibronectin binding protein or polypeptide.
11. A fibronectin binding protein or polypeptide comprising at least one of the amino acid sequences

**0 294 349**

Gly Gln Asn Ser Gly Asn Gln Ser Phe Glu Glu Asp Thr Glu Glu Asp Lys Pro Lys Tyr Glu Gln Gly Gly Asn Ile  
Val Asp Ile Asp Phe Asp Ser Val Pro Gln Ile His

5

Gly Gln Asn Lys Gly Asn Gln Ser Phe Glu Glu Asp Thr Glu Lys Asp Lys Pro Lys Tyr Glu His Gly Gly Asn Ile  
Ile Asp Ile Asp Phe Asp Ser Val Pro His Ile His

Gly Phe Asn Lys His Thr Glu Ile Ile Glu Glu Asp Thr Asn Lys Asp Lys Pro Ser Tyr Gln Phe Gly Gly His Asn  
Ser Val Asp Phe Glu Glu Asp Thr Leu Pro Lys Val

10

15

20

25

30

35

40

45

50

55

60

65




FIG. 1A




FIG. 1B

0294349




FIG. 2

0294349



RESTRICTION MAP

FIG. 3



0294349




FIG. 4




FIG. 5

0294349

A

B




FIG. 6




FIG. 7

FIG. 8A:1

101	100	99	98	97	96	95	94	93	92	91	90	89	88	87	86	85	84	83	82	81	80	79	78	77	76	75	74	73	72	71	70	69	68	67	66	65	64	63	62	61	60	59	58	57	56	55	54	53	52	51	50	49	48	47	46	45	44	43	42	41	40	39	38	37	36	35	34	33	32	31	30	29	28	27	26	25	24	23	22	21	20	19	18	17	16	15	14	13	12	11	10	9	8	7	6	5	4	3	2	1
101	100	99	98	97	96	95	94	93	92	91	90	89	88	87	86	85	84	83	82	81	80	79	78	77	76	75	74	73	72	71	70	69	68	67	66	65	64	63	62	61	60	59	58	57	56	55	54	53	52	51	50	49	48	47	46	45	44	43	42	41	40	39	38	37	36	35	34	33	32	31	30	29	28	27	26	25	24	23	22	21	20	19	18	17	16	15	14	13	12	11	10	9	8	7	6	5	4	3	2	1
101	100	99	98	97	96	95	94	93	92	91	90	89	88	87	86	85	84	83	82	81	80	79	78	77	76	75	74	73	72	71	70	69	68	67	66	65	64	63	62	61	60	59	58	57	56	55	54	53	52	51	50	49	48	47	46	45	44	43	42	41	40	39	38	37	36	35	34	33	32	31	30	29	28	27	26	25	24	23	22	21	20	19	18	17	16	15	14	13	12	11	10	9	8	7	6	5	4	3	2	1
101	100	99	98	97	96	95	94	93	92	91	90	89	88	87	86	85	84	83	82	81	80	79	78	77	76	75	74	73	72	71	70	69	68	67	66	65	64	63	62	61	60	59	58	57	56	55	54	53	52	51	50	49	48	47	46	45	44	43	42	41	40	39	38	37	36	35	34	33	32	31	30	29	28	27	26	25	24	23	22	21	20	19	18	17	16	15	14	13	12	11	10	9	8	7	6	5	4	3	2	1
101	100	99	98	97	96	95	94	93	92	91	90	89	88	87	86	85	84	83	82	81	80	79	78	77	76	75	74	73	72	71	70	69	68	67	66	65	64	63	62	61	60	59	58	57	56	55	54	53	52	51	50	49	48	47	46	45	44	43	42	41	40	39	38	37	36	35	34	33	32	31	30	29	28	27	26	25	24	23	22	21	20	19	18	17	16	15	14	13	12	11	10	9	8	7	6	5	4	3	2	1
101	100	99	98	97	96	95	94	93	92	91	90	89	88	87	86	85	84	83	82	81	80	79	78	77	76	75	74	73	72	71	70	69	68	67	66	65	64	63	62	61	60	59	58	57	56	55	54	53	52	51	50	49	48	47	46	45	44	43	42	41	40	39	38	37	36	35	34	33	32	31	30	29	28	27	26	25	24	23	22	21	2																			

0294349

FIG. 8A.2

His Glu Asn Ser Lys His His Ala Asp Val Val Glu Tyr Glu Glu Asp Thr Asn Pro Gly Gly Gly Gln Val Thr Thr Glu Ser Asn Leu  
CAT GAA AAT TCA AAA CAT CAC GCT GAT GGT GAT GAA TAT GAA TAT GAA GAT ACA GAT ACA AAC CCA GGT GGT GGT GGT GGT ACT ACT GAG TCT AAC TTA  
610  
1994  
Val Glu Phe Asp Glu Glu Ser Thr Lys Glu Val Val Thr Thr Thr Lys Glu Tyr Thr Thr Thr  
GTT GAA TTT GAC GAA GAG TCT ACA AAA GGT ATT GTA ACT GGC GCA GTG AGC GAT CAT ACA ACA GAT GAA GAT ACB AAA GAA TAT ACA ACT  
640  
2084  
Glu Ser Asn Leu Ile Glu Leu Val Asp Glu Leu Pro Glu Glu His Glu Glu Gln Ala Gln Gln GGA CCA GTC GAG GAA ATT ACT AAA Asn Asn His  
GAA AGT AAT CTG ATT GAA TTA GTG GAT GAA TTA CCT GAA GAG CAT GGT CAA GCA CAA GGA CCA GTC GAG GAA AAT ACT AAA AAC AAT CAT  
670  
2174  
His Ile Ser His Ser Glu Leu Glu Tyr Glu  
CAT ATT TCT CAT TCT GGT TTA GGA ACT GAA AAT GGT CAC GGC AAT TAT GAC GTG AAT GAA GAA AAT GAA AAT GAA AAT GAA AAT GAA AAT GAA AAT  
700  
2264  
Lys Ser Glu Leu Glu Tyr Glu  
AAG AGT GAA TTA GGT TAT GAA GGT GGC CAA AAT AGC GGT AAC CAG TCA TTC GAG GAA GAC ACA GAA GAA GAA GAA GAA GAA GAA GAA GAA GAA  
730  
2354  
Gly Gly Asn Ile Val Asp Ile Asp Phe Asp Ser Val Pro Gln Ile His Gly Gln Asn Lys Gly Asn Gln Ser Phe Glu Glu Asp Thr Glu  
GGT GGC AAT ATC GTA GAT ATC GAT TTT GAT  
760  
2444  
Lys Asp Lys Pro Lys Tyr Glu His Glu  
AAA GAC AAA CCT AAG TAT GAA CAT GGC GGT AAC ATC AAT GAT ATC GAT ATC GAT ATC GAT ATC GAT ATC GAT ATC GAT ATC GAT ATC GAT  
790  
2534  
Glu Ile Ile Glu Glu Asp Thr Asn Lys Asp Lys Pro Ser Tyr Glu Phe Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu  
GAA ATT ATT GAA GAA GAT ACA AAT AAA GAT AAA GAT AAA GAT AAA GAT AAA GAT AAA GAT AAA GAT AAA GAT AAA GAT AAA GAT AAA  
820  
2624  
Lys Val Ser Gly Gln Asn Glu  
AAA GTA AGC GGC CAA AAT GAA GGT CAA CAA ACG ATT GAA GAA GAT ACA AAT GAT AAA GAT AAA GAT AAA GAT AAA GAT AAA GAT AAA  
850  
2714  
Pro Ser Glu Pro Glu Thr Pro Thr Pro Thr Pro Thr Pro Thr Pro Thr Pro Thr Pro Thr Pro Thr Pro Thr Pro Thr Pro Thr  
CCA AGT GAG CCG GAA ACA CCA ACG CCA CCA ACG CCA CCA ACG CCA CCA ACG CCA CCA ACG CCA CCA ACG CCA CCA ACG CCA CCA ACG  
880  
2804  
Glu Pro Glu Thr Pro Thr Pro Thr Pro Thr Pro Thr Pro Thr Pro Thr Pro Thr Pro Thr Pro Thr Pro Thr Pro Thr Pro Thr  
GAG CCA GAA ACT CCA ACA CCG CCA ACA CCA GAG GTA CCA GCT GAA CCA CCA GCT GAA CCA CCA GCT GAA CCA CCA GCT GAA CCA CCA  
910  
2894  
Ser Lys Pro Val Glu Gln Gly Lys Val Val Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr  
TCT AAA CCA GTG GAA CAA GGT AAA GTA GTA ACA CCT GGT ATT GAA ATC AAT GAA AAG GGT AAA GAA GAA GAA GAA GAA GAA GAA GAA  
940  
2984  
Ser Lys Lys Ser Glu Leu Pro Glu Thr Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu Glu  
TCT AAG AAA TCT GAA CTA CCT GAA ACA GGT GGA GAA GAA TCA ACA AAC AAA GGT ATG TTG TTC GGC GGA TTA TTC AGC ATT CTA GGT TTA  
970  
3074  
Ala Leu Leu Arg Arg Asn Lys Lys Asn His Lys Ala \*\*\*  
GCA TTA TTA CGC AGA AAT AAA AAG AAT CAC AAA OCA TAA TAAACAAAATTGACGGGTTTATTTTCATATAATATATATGAGTAAAGCTGTTTATTAATCAA  
982  
3181  
ATTCTAATAGAAAATTAGGTGTTTCTGATGCTT :ATTGGTTTATGTCGTGATGATGATAACGAACTGAGAGATAAAGTTAGAAATTTTAAACTAGT  
3280

0294349




Fig 9.